Saturday, September 13, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Consumer & Luxury

Caleres Stock Navigates Volatile Week Amid Mixed Signals

Felix Baarz by Felix Baarz
September 13, 2025
in Consumer & Luxury, Earnings, Mergers & Acquisitions, Turnaround
0
Caleres Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Caleres investors experienced a dramatic week of trading as conflicting corporate developments sent the footwear company’s shares on a turbulent ride. The market initially reacted negatively to disappointing quarterly results before reversing course on acquisition-driven optimism, leaving analysts divided about the company’s near-term prospects.

Quarterly Performance Falls Short

The company’s second quarter 2025 financial release delivered underwhelming results to shareholders. While revenue reached $658.5 million, meeting projections, it represented a 3.6% decline compared to the same period last year. More significantly, adjusted earnings per share came in at $0.35, substantially below the anticipated range of $0.51 to $0.56. This earnings miss triggered an immediate selloff that drove the stock price down more than 16%.

Acquisition Sparks Investor Optimism

Market sentiment shifted dramatically just one day later when shares surged 11.4% as investors reassessed the company’s recent strategic acquisition. Caleres completed its $120.2 million purchase of luxury brand Stuart Weitzman, with management projecting both enhanced premium positioning and operational synergies in logistics and distribution. This move appears to be part of a broader strategy to strengthen the company’s market position despite current challenges.

Should investors sell immediately? Or is it worth buying Caleres?

Macroeconomic Headwinds Persist

The company faces ongoing pressure from tariff uncertainties, which forced management to withdraw its annual guidance—a concerning development for market observers. These tariff impacts have compressed gross margins by 210 basis points to 43.4%. In response to these challenges, Caleres has implemented structural adjustments aimed at achieving $15 million in annual cost savings, with half of these savings expected to materialize within the current fiscal year.

Analyst Community Maintains Cautious Stance

Market experts remain skeptical about the company’s near-term outlook. Telsey Advisory Group revised its third quarter 2026 estimates downward from $1.02 to $0.85 per share, citing difficult market conditions. The consensus price target among analysts currently stands at $14.00 with a “Reduce” rating, indicating continued caution about the stock’s prospects.

The critical question facing investors is whether the Stuart Weitzman acquisition can sufficiently offset structural challenges including tariff pressures and softening consumer demand. The company’s next quarterly results will provide crucial insight into whether this strategic move can deliver the anticipated benefits.

Ad

Caleres Stock: Buy or Sell?! New Caleres Analysis from September 13 delivers the answer:

The latest Caleres figures speak for themselves: Urgent action needed for Caleres investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 13.

Caleres: Buy or sell? Read more here...

Tags: Caleres
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Acacia Research Stock
Analysis

Acacia Research Shares Plummet Despite Record Revenue Growth

September 13, 2025
Northeast Bancorp Stock
Banking & Insurance

Institutional Investors Flock to Northeast Bancorp on Strong Quarterly Performance

September 13, 2025
MP Materials Stock
Commodities

MP Materials Shares Face Selling Pressure Despite Robust Financial Results

September 13, 2025
Next Post
Hbt Financial Stock

HBT Financial: Strong Fundamentals Face Off Against Rising Short Interest

Karat Packaging Stock

The Curious Case of Karat Packaging's Market Mismatch

Nike Stock

Nike Shares Face Mounting Pressure as Key Earnings Report Looms

Recommended

Five Bancorp Stock

Regional Banks Face Fed Policy Crossroads as Five Bancorp Shares Fluctuate

1 week ago
Cheniere Energy Stock

America’s Quiet Energy Giant Powers Global Transition

3 weeks ago
Dow Inc Stock

Dow Secures Major $540 Million Infrastructure Investment Amid Market Challenges

2 weeks ago
AMT stock news

Strategic Acquisition: SG Americas Securities LLC Invests in RxSight, Inc. to Drive Medical Technology Advancements

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alphabet Amazon AMD AMZN Apple BA BigBear.ai BioNTech Broadcom Coinbase DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF MSFT NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir Pepsi Realty Income Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla Tilray TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Institutional Investors Flock to Northeast Bancorp on Strong Quarterly Performance

Landmark Ruling Secures Alphabet’s Core Business Model

MP Materials Shares Face Selling Pressure Despite Robust Financial Results

Aviat Networks Stock Surges on Stellar Earnings and Analyst Upgrade

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

Is Blue Foundry Bancorp a Hidden Gem or a Value Trap?

Trending

Viking Therapeutics Stock
Analysis

Viking Therapeutics Faces Investor Scrutiny Over Weight-Loss Drug Tolerability

by Robert Sasse
September 13, 2025
0

Investors are reassessing Viking Therapeutics' clinical trial data as concerns emerge about patient discontinuation rates in the...

Orange County Stock

Orange County Bancorp: A Tale of Steady Dividends and Mounting Credit Concerns

September 13, 2025
Acacia Research Stock

Acacia Research Shares Plummet Despite Record Revenue Growth

September 13, 2025
Northeast Bancorp Stock

Institutional Investors Flock to Northeast Bancorp on Strong Quarterly Performance

September 13, 2025
Alphabet Stock

Landmark Ruling Secures Alphabet’s Core Business Model

September 13, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Viking Therapeutics Faces Investor Scrutiny Over Weight-Loss Drug Tolerability September 13, 2025
  • Orange County Bancorp: A Tale of Steady Dividends and Mounting Credit Concerns September 13, 2025
  • Acacia Research Shares Plummet Despite Record Revenue Growth September 13, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com